Recombinant SARS-CoV-2 3CL Protease, CF

GC376 achieves 50% inhibition of 30 nM SARS-CoV-2 3CL Protease (E-720) at a concentration of 54-71 nM.

SDS-PAGE of Recombinant SARS-CoV-2 3CL Protease. 1 μg and 2 μg of Recombinant SARS-CoV-2 3CL Protease (Catalog # E-720) was resolved with SDS-PAGE under reducing conditions and visualized by colloidal Coomassie Blue staining, showing a band at 34 kDa.

LC-MS analysis of SARS-CoV-2 3CL Protease. SARS-CoV-2 3CL Protease (Catalog # E-720) was analyzed by a Thermo Q Exactive HF instrument then deconvoluted using Thermo BioPharma Finder software. The expected monoisotopic mass is 33774.478 Da.

• Reactivity: V
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant SARS-CoV-2 3CL Protease, CF Summary

• Additional Information: E. coli Expressed, Bioactivity Tested
• Details of Functionality: Recombinant SARS-CoV-2 3CL Protease is a cysteine protease that cleaves proteins with sequences including LQ(S/A/G). The cleavage occurs c-terminal to the glutamine residue. Reaction conditions will need to be optimized for each specific application. We recommend an initial SARS-CoV-2 3CL Protease concentration of 20-40 nM when using substrate S-720.
• Source: E. coli-derived sars-cov-2 3CL Protease protein
  Ser1 - Gln306
• Accession #: YP_009725301.1
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 34 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
• Buffer: Supplied as a solution in HEPES, NaCl, DTT and EDTA.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant SARS-CoV-2 3CL Protease, CF

• 3CL Protease
• 3CL Proteinase
• 3C-like main protease
• 3CL-Mpro
• COVID-19
• M Proteinase
• Main Protease
• Mpro

Background

The 3CL protease (aka 3CL^pro, M^pro or "Main" Protease) from the human SARS-CoV-2 coronavirus (Severe Acute Respiratory Syndrome coronavirus 2) is a C30-type cysteine protease located within the non-structural proteins 3 (NS3) section of the viral polypeptide.  3CL^pro activity is required to process the viral polyprotein into functional, mature subunits, and there are 11 or more sites of cleavage, many containing the sequence LQ[S/A/G]; the protease cleaves c-terminal to the glutamine amino acid.  Along with the CoV-2 Papain-Like Protease (catalog number E-611), 3CL^pro presents an attractive target for therapeutic intervention for COVID-19.  Because no human proteases with a similar cleavage specificity are known, inhibitors of 3CL^pro are unlikely to cause mechanism-based toxicity.  

1. Chen Y.W., et al. (2020) F1000Res. 9:129.
2. Pillaiyar T., et al. (2016) J. Med. Chem.  59: 6595.
3. Zhang L., et al. (2020) Science 368:409.

Publications for SARS-CoV-2 3CL Protease (E-720)(2)

Publications using E-720

• Suresh, V;Sheik, DA;Detomasi, TC;Zhao, T;Zepeda, T;Saladi, S;Rajesh, UC;Byers, K;Craik, CS;Davisson, VJ; A Prototype Assay Multiplexing SARS-CoV-2 3CL-Protease and Angiotensin-Converting Enzyme 2 for Saliva-Based Diagnostics in COVID-19 Biosensors 2023-06-27 [PMID: 37504081] (Bioassay)
• K Zhu, MJ Suskiewicz, A Hloušek-Ka, H Meudal, A Miko?, V Aucagne, D Ahel, I Ahel DELTEX E3 ligases ubiquitylate ADP-ribosyl modification on protein substrates Science Advances, 2022-10-05;8(40):eadd4253. 2022-10-05 [PMID: 36197986] (Bioassay, Human)

Bioinformatics

• Uniprot:
  • YP_009725301.1(SARS-CoV-2)